Impact of renal replacement therapy strategy on beta-lactam plasma concentrations: the BETAKIKI study—an ancillary study of a randomized controlled trial

Annals of Intensive Care

Table 2 Type of beta-lactam therapy, site of infection and microorganisms

	Total (N = 112)
Type of Beta-lactam^a
• Amoxicillin	11
• Amoxicillin + clavulanate	7
• Cloxacillin	6
• Piperacillin	4
• Piperacillin + tazobactam	23
• Cefotaxime	37
• Ceftriaxone	16
• Ceftazidime	3
• Imipenem	10
Site of infection
• Bloodstream infection	29
• Pneumonia	23
• Abdominal infection	19
• Urinary tract infection	11
• Meningitis	4
• Skin and soft tissue infection	8
• Other	5
• None	13
Identified microorganisms^b
Gram positive
• Streptococcus pneumoniae	6
• Other Streptococcus	7
• Staphylococcus aureus	12
• Coagulase negative Staphylococcus	4
• Enterococcus sp.	6
Gram negative
• Haemophilus sp.	3
• Escherichia coli	27
• Klebsiella pneumoniae	14
• Other Enterobacteriaceae	16
• Pseudomonas aeruginosa	8
• Legionella pneumophila	3
• Other	6